<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733340</url>
  </required_header>
  <id_info>
    <org_study_id>Bacteria clean pre-allo-HSCT</org_study_id>
    <nct_id>NCT03733340</nct_id>
  </id_info>
  <brief_title>Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT</brief_title>
  <official_title>Antibacterial Prophylaxis With Imipenem vs no Prophylaxis for Hematological Malignancies Patients Before Allogenetic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative
      treatment for a variety of hematologic malignancies. Bacterial infections remain a common
      complication of allo-HSCT, especially in the pre-engraftment phase. Pre-engraftment
      neutropenia typically lasts for up to 2 weeks in autologous HSCT but is considerably longer
      in allogeneic HSCT recipients who receive myeloablative conditioning regimens. This is a
      prospective, randomized, controlled, phase II/III clinical trial that aims to investigate the
      beneficial and harmful effects of prophylactic use of imipenem in patients with hematological
      malignancies before allo-HSCT. All patients aged above 14 years, diagnosed with hematological
      malignancies and ready to undergo allo-HSCT, no active infection within 3 weeks before
      allo-HSCT, with a normal CT scan-chest before entering the transplantation cabin and willing
      to participate in the trial will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infectious incidence</measure>
    <time_frame>pre-engraftment in allo-HSCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVHD</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Antibacterial Prophylaxis</condition>
  <condition>Hematological Malignancies</condition>
  <condition>Allogenetic Hematopoietic Stem Cell Transplantation</condition>
  <condition>Imipenem</condition>
  <arm_group>
    <arm_group_label>Imipenem prophylaxis group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imipenem: 1g q8h i.v. daily for 5 consecutive days before the onset of conditioning of allo-HSCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blank control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Without antibacterial prophylaxis at the onset of condition of all-HSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem</intervention_name>
    <description>Imipenem: A wide-spectre antibiotic from the carbapenem group Other name: Imipenem-cilastatin</description>
    <arm_group_label>Imipenem prophylaxis group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged above 14 years;

          -  diagnosis with hematological malignancies and be ready to undergo allo-HSCT;

          -  no active infection within 3 weeks before allo-HSCT;

          -  with a normal CT scan-chest before entering the transplantation cabin.

        Exclusion Criteria:

          -  age &lt; 14 years;

          -  active and documented infection at admission;

          -  with a abnormal CT scan-chest before entering the transplantation cabin;

          -  with any conditions not suitable for the trial;

          -  unwilling to participate in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liu Qifa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhao Ke</last_name>
    <phone>+86-020-61641613</phone>
    <email>124821741@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao Ke</last_name>
      <phone>+86-020-61641613</phone>
      <email>124821741@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Liu Qifa</last_name>
      <phone>+86-020-61641613</phone>
    </contact_backup>
    <investigator>
      <last_name>Liu Qifa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

